Search

AF solution

Chevron
Endometrial Cancer Organoid_maian
Cancer Organoid

Endometrial Cancer Organoid

Endometrial Cancer Organoid_maian

  • Accurate Predictions and Personalized Treatment
    ▶ Endometrial cancer organoids replicate patient tumors for precise predictions and tailored treatments.
  • Efficient Drug Testing and Time-Saving
    ▶ Rapid drug testing with endometrial cancer organoids reduces research time and enhances reliability.
  • Advanced Research and Innovation
    ▶ Cutting-edge organoid models surpass traditional methods, advancing cancer research and treatment solutions.

Organism
Human
Product Type
Organoid
Tissue
Endometrial cancer
Disease
Endometrial cancer

Applications

Oncology

The oncology drug efficacy evaluation platform is based on patient-derived organoids(PDOs).
This platform allows for the assessment of the efficacy of oncology agents and immunotherapeutics by utilizing a co-culture system with immune cells from the tumor microenvironment.

Immuno-Oncology

This provides a solution for assessing the effectiveness of immunotherapeutic agents targeting cytotoxic T cells in co-culture with cancer organoids.

Tumormicroenvironment

CAFs promote cancer invasion and metastasis, potentially inducing resistance to anticancer drugs.
Considering these functions of CAFs is crucial for accurately assessing the efficacy of anticancer drugs and developing strategies to address these challenges.

Cancer Vaccine

Lead the future of treatment with our innovative cancer vaccine and mRNA therapy platform.
Discover advanced solutions that provide better health and hope through our cutting-edge technology and scientific approach

Table of Contents

Enhance Endometrial Cancer Studies with Our Organoid Service

Utilize our precision-engineered endometrial cancer organoids for effective therapy development and detailed tumor analysis. These organoids replicate patient tumor characteristics, offering a robust model for exploring targeted treatments and hormone dynamics. Transform endometrial cancer research and accelerate discovery with our advanced organoid platform.

Endometrial Cancer Organoid

Validation of Biomarker Expression in Endometrial Cancer Organoids Mirrors Patient Tissue

We performed immunofluorescence staining on our endometrial cancer organoids to confirm their similarity to patient tissue. The results demonstrated that both pan-cytokeratin (Pan-CK), an epithelial cell marker, and Vimentin (VIM), an endometrial cancer tumor marker, were expressed in a pattern similar to the patient tissue. Additionally, the expression of anti-estrogen receptor (ER-α) and anti-progesterone receptor (PR) in the organoids mirrored that in the patient tissue. These organoids, which faithfully replicate the cellular and molecular characteristics of the primary tumor, offer a powerful platform for developing and testing targeted treatments, studying tumor behavior, and exploring hormone receptor dynamics in endometrial cancer.

H&E
Pan-CK
VIM
ER-a
PR

Cancer tissue

Cancer organoid

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.